GRF2 Antikörper

Produktnummer ABIN2192053

Dieses Ratte Monoklonal-Antikörper erkennt spezifisch GRF2 in IP und IA. Er zeigt eine Reaktivität gegenüber Human und wurde in 2+ Publikationen erwähnt.

Kurzübersicht für GRF2 Antikörper (ABIN2192053)

Target: GRF2 (RAPGEF1) (Rap Guanine Nucleotide Exchange Factor (GEF) 1 (RAPGEF1))

Reaktivität: Human

Wirt: Ratte

Klonalität: Monoklonal

Konjugat: Dieser GRF2 Antikörper ist unkonjugiert

Applikation: Immunoprecipitation (IP), Immunoassay (IA)

Klon: 9

Produktdetails anti-GRF2 Antikörper

Sterilität: 0.2 μm filtered

Anwendungsinformationen

Applikationshinweise: of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes. Vox Sang 1983, 45: 367 4. Chaplin, H et al, Further studies of the C3g component of the alpha 2D fragment of human C3. Clin Exp Immunol 1983, 51: 639 5. Mollnes, T et al, Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay. J Immunol Methods 1987, 101: 201

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.02 % sodium azide and 0.1 % bovine serum albumin.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Haltbarkeit: 12 months

Referenzen für anti-GRF2 Antikörper (ABIN2192053)

Lachmann, Pangburn, Oldroyd: "Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies." in: The Journal of experimental medicine, Vol. 156, Issue 1, pp. 205-16, (1982) (PubMed).

Lachmann, Oldroyd, Milstein, Wright: "Three rat monoclonal antibodies to human C3." in: Immunology, Vol. 41, Issue 3, pp. 503-15, (1981) (PubMed).

Details zu GRF2

Target: GRF2 (RAPGEF1) (Rap Guanine Nucleotide Exchange Factor (GEF) 1 (RAPGEF1))

Andere Bezeichnung: c3g

Hintergrund: The monocolonal antibody 9 (also known as YB2/90-5-20) reacts with a neoantigen on iC3, iC3b, C3dg and C3g. C3g itself however is a small fragment probably not formed in vivo. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. An inherited deficiency of C3 predisposes the person to frequent bacterial infections. C3 fragments are deposited in tissues at sites of antibody-mediated immunopathology. In ulcerative colitis and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by C3-convertases results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b and C3f. iC3b is further processed into C3c and C3dg. C3dg can be cleaved into C3d and C3g though this does not occur in plasma. The monoclonal antibody 9 recognizes iC3b, C3dg and C3g in plasma. The monoclonal antibody does not recognize C3 or C3b.

Pathways: Interferon-gamma Pathway, Neurotrophin Signalübertragung, Platelet-derived growth Factor Receptor Signaling, Signaling of Hepatocyte Growth Factor Receptor